{"id":434907,"date":"2025-12-18T00:00:00","date_gmt":"2025-12-18T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/dlsfim0007-2025-biopharma-rheumatoid-arthritis-landscape-forecast-disease-landscape-forecast-g7\/"},"modified":"2026-04-14T10:10:50","modified_gmt":"2026-04-14T10:10:50","slug":"dlsfim0007-2026-biopharma-rheumatoid-arthritis-landscape-forecast-disease-landscape-forecast-g7","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/dlsfim0007-2026-biopharma-rheumatoid-arthritis-landscape-forecast-disease-landscape-forecast-g7\/","title":{"rendered":"Rheumatoid Arthritis &#8211; Landscape &#038; Forecast &#8211; Disease Landscape &#038; Forecast (G7)"},"content":{"rendered":"<p>Although <abbr title=\"tumor necrosis factor\">TNF<\/abbr>-alpha inhibitors remain the most widely prescribed biologics for rheumatoid arthritis (<abbr title=\"rheumatoid arthritis\">RA<\/abbr>) refractory to conventional <abbr title=\"disease-modifying antirheumatic drug\">DMARD<\/abbr> treatment (the first-line standard of care), the <abbr title=\"rheumatoid arthritis\">RA<\/abbr> drug market boasts a variety of targeted agents from many drug classes, all competing largely for a share of the <abbr title=\"tumor necrosis factor\">TNF<\/abbr>-refractory population. The continued launch of biosimilars in the major pharmaceutical markets will only add to the competition. Increasing safety concerns surrounding the <abbr title=\"Janus-activated kinase\">JAK<\/abbr> inhibitor class have delayed their use until after anti-<abbr title=\"tumor necrosis factor\">TNF<\/abbr> drugs in the United States, reducing their overall uptake. Although the late-phase pipeline for <abbr title=\"rheumatoid arthritis\">RA<\/abbr> is sparse, the sheer number of biologics and targeted oral therapies available to treat the disease ensures that marketers will face fierce competition and increasing challenges to gain and maintain market share.<\/p>\n<p><strong>Questions answered<\/strong><\/p>\n<ul class=\"round-bullets\">\n<li>What are physicians\u2019 preferred <abbr title=\"tumor necrosis factor\">TNF<\/abbr>-alpha inhibitors for <abbr title=\"rheumatoid arthritis\">RA<\/abbr>, and what factors drive these preferences? Given the increasingly fragmented market, how likely are physicians to cycle through anti-<abbr title=\"tumor necrosis factor\">TNF<\/abbr> agents before progressing to a novel mechanism of action?<\/li>\n<li>How has \/ will the entry and continued uptake of biosimilars affect sales and patient shares of currently marketed <abbr title=\"rheumatoid arthritis\">RA<\/abbr> agents and emerging therapies?<\/li>\n<li>What are physicians\u2019 perceptions of currently marketed non-<abbr title=\"tumor necrosis factor\">TNF<\/abbr> biologics and oral <abbr title=\"Janus-activated kinase\">JAK<\/abbr> inhibitors for <abbr title=\"rheumatoid arthritis\">RA<\/abbr>? Where are these agents positioned in the treatment algorithm, and which agents have been most successful in targeting the <abbr title=\"tumor necrosis factor\">TNF<\/abbr>-refractory population?<\/li>\n<li>What are the drivers and constraints in the <abbr data-abbreviation-entity=\"5656\" title=\"rheumatoid arthritis\">RA<\/abbr> therapy market, and how will the market evolve over the forecast period?<\/li>\n<\/ul>\n<p><strong>Content highlights<\/strong><\/p>\n<p>Markets covered: United States, <abbr title=\"France, Germany, Italy, Spain, UK\">EU5<\/abbr>, Japan<\/p>\n<p>Primary research: 29 country-specific interviews with thought-leading rheumatologists<\/p>\n<p>Epidemiology: Number of total, diagnosed, and drug-treated prevalent cases of <abbr title=\"rheumatoid arthritis\">RA<\/abbr> by country; number of diagnosed prevalent cases of <abbr title=\"rheumatoid arthritis\">RA<\/abbr> by severity<\/p>\n<p>Forecast: 10-year, annualized, drug-level sales and patient share of key <abbr data-abbreviation-entity=\"5656\" title=\"rheumatoid arthritis\">RA<\/abbr>\u00a0therapies through 2034, segmented by brands \/ generics \/ biosimilars<\/p>\n<p>Drug treatments: Coverage of key current and late-phase emerging therapies<\/p>\n<p><strong>Product description<\/strong><\/p>\n<p>Disease Landscape &#038; Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current and emerging therapies, and drug forecasts supported by detailed primary and secondary research, enabling you to:<\/p>\n<ul class=\"round-bullets\">\n<li>Optimize your long-term disease and development strategy.<\/li>\n<li>Quantify market potential for your pipeline assets and those of your competitors.<\/li>\n<li>Understand a disease from top to bottom, including key patient populations, the current and future therapeutic landscape, and the evolving market trajectory.<\/li>\n<li>Gauge the commercial outlook and impact of key market events.<\/li>\n<\/ul>\n","protected":false},"template":"","class_list":["post-434907","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-rheumatoid-arthritis","biopharma-therapy-areas-rheumatology","biopharma-date-2297"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/434907","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":3,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/434907\/revisions"}],"predecessor-version":[{"id":575249,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/434907\/revisions\/575249"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=434907"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}